Emerging targeted therapies for melanoma treatment (Review)

被引：38

作者：

Russo, Angela ^{[1
]}

Ficili, Bartolomea ^{[1
]}

Candido, Saverio ^{[1
]}

Pezzino, Franca Maria ^{[1
]}

Guarneri, Claudio ^{[2
]}

Biondi, Antonio ^{[3
]}

Travali, Salvatore ^{[1
]}

McCubrey, James A. ^{[4
]}

Spandidos, Demetrios A. ^{[5
]}

Libra, Massimo ^{[1
]}

机构：

[1] Univ Catania, Dept Biomed Sci, Sect Gen Pathol & Oncol, Lab Translat Oncol & Funct Genom, I-95124 Catania, Italy

[2] Univ Messina, Dept Social Territorial Med, Dermatol Sect, I-98125 Messina, Italy

[3] Univ Catania, Dept Surg, I-95124 Catania, Italy

[4] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA

[5] Univ Crete, Sch Med, Dept Virol, Iraklion 71003, Crete, Greece

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2014年 / 45卷 / 02期

关键词：

melanoma; MAPK/AKT pathway; targeted therapies; IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES; OVERCOME ACQUIRED-RESISTANCE; PHASE-II TRIAL; B-RAF; METASTATIC MELANOMA; CLINICAL DEVELOPMENT; PIK3CA MUTATIONS; BRAF INHIBITORS; OPEN-LABEL; IN-VITRO;

D O I：

10.3892/ijo.2014.2481

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development of novel therapies for this devastating disease. In melanoma, both the Ras/Raf/MEK/ERK (MAPK) and the PI3K/AKT (AKT) signalling pathways are constitutively activated through multiple mechanisms. Targeting various effectors of these pathways with pharmacologic inhibitors may inhibit melanoma cell growth and angiogenesis. Ongoing clinical trials provide hope to improve progression-free survival of patients with advanced melanoma. This review summarizes the most relevant studies focused on the specific action of these new molecular targeted agents. Mechanisms of resistance to therapy are also discussed.

引用

页码：516 / 524

页数：9

共 50 条

[21] Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
Komatsubara, Kimberly M.
Carvajal, Richard D.
CURRENT ONCOLOGY REPORTS, 2017, 19 (07)
[22] Targeted Therapies for Cutaneous Melanoma
Kee, Damien
McArthur, Grant
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (03) : 491 - 505
[23] Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
Kimberly M. Komatsubara
Richard D. Carvajal
Current Oncology Reports, 2017, 19
[24] Targeted melanoma therapies as radiosensitizers
Smith, Jessica L.
Chang, Cecilia
Wang, Tim
Rizos, Helen
Shen, Han
Carlino, Matteo
Hau, Eric
CANCER RESEARCH, 2019, 79 (13)
[25] New Targeted Therapies in Melanoma
Kudchadkar, Ragini R.
Gonzalez, Rene
Lewis, Karl
CANCER CONTROL, 2013, 20 (04) : 282 - 288
[26] Targeted Therapies for Metastatic Melanoma
Chandra, Sunandana
Pavlick, Anna C.
DERMATOLOGIC CLINICS, 2012, 30 (03) : 517 - +
[27] Targeted therapies in metastatic Melanoma
Hauschild, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 38 - 39
[28] Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
Milic, Sandra
Mikolasevic, Ivana
Krznaric-Zrnic, Irena
Stanic, Marija
Poropat, Goran
Stimac, Davor
Vlahovic-Palcevski, Vera
Orlic, Lidija
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4835 - 4845
[29] Telomere-Based Cancer Treatment: Emerging Targeted Therapies
Chen, Michele
McLeskey, Sandra W.
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (06) : 720 - 726
[30] Emerging molecular targeted therapies in the treatment of head and neck cancer
Bozec, Alexandre
Peyrade, Frederic
Fischel, Jean-Louis
Milano, Gerard
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (02) : 299 - 310

← 1 2 3 4 5 →